The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Sun., Jul. 3, 4:39 PM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #52. AstraZeneca Bristol-Myers Squibb Diabetes Business

Acquirer: AstraZeneca (AZN)
Acquiree: Bristol-Myers Squibb Diabetes Business (BMY)
Details: Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has signed an agreement to sell its global diabetes business that was part of its collaboration with AstraZeneca. Under terms of the agreement, AstraZeneca will make an upfront payment of $2.7 billion to Bristol-Myers Squibb, with potential regulatory- and sales-based milestone payments of up to $1.4 billion and will make royalty payments based on net sales through 2025. In addition, AstraZeneca will make payments of up to $225 million if and when certain assets are subsequently transferred. The Bristol-Myers Squibb Board of Directors has approved this transaction.

AstraZeneca is a holding company. Through its subsidiaries, Co. is engaged in biopharmaceutical business focusing on the research, development and commercialization of prescription medicines. Co. focuses on disease areas that include Oncology; BioPharmaceuticals; Rare Disease; and Other Medicines and COVID-19. Key marketed products within the area of oncology include among other, Tagrisso (osimertinib) for lung cancer and Lynparza (olaparib) for ovarian cancer. Key marketed products within the area of Other Medicines and COVID-19 include among other, Synagis (palivizumab) for respiratory syncytial virus; and Evusheld (tixagevimab co-packaged with cilgavimab) for COVID-19.

Open the AZN Page at The Online Investor »

AstraZeneca is a holding company. Through its subsidiaries, Co. is engaged in biopharmaceutical business focusing on the research, development and commercialization of prescription medicines. Co. focuses on disease areas that include Oncology; BioPharmaceuticals; Rare Disease; and Other Medicines and COVID-19. Key marketed products within the area of oncology include among other, Tagrisso (osimertinib) for lung cancer and Lynparza (olaparib) for ovarian cancer. Key marketed products within the area of Other Medicines and COVID-19 include among other, Synagis (palivizumab) for respiratory syncytial virus; and Evusheld (tixagevimab co-packaged with cilgavimab) for COVID-19.

Open the BMY Page at The Online Investor »

Company Name: 
AstraZeneca Plc
Website: 
www.astrazeneca.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding AZN: 
15
Total Market Value Held by ETFs: 
$687.32M
Total Market Capitalization: 
$33.00B
% of Market Cap. Held by ETFs: 
2.08%
Company Name: 
Bristol Myers Squibb Co.
Website: 
www.bms.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding BMY: 
128
Total Market Value Held by ETFs: 
$21.46B
Total Market Capitalization: 
$166.66B
% of Market Cap. Held by ETFs: 
12.88%
 

Quotes delayed 20 minutes

Email EnvelopeFree Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Drugs & Pharmaceuticals M&A - Slide 52 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.